MAM
RVNC

Martingale Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Martingale Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,914
Closed -$806K – 906
2021
Q3 		$806K Buy
28,914
+21,500
+290% +$614K 0.01% 558
2021
Q2 		$220K Buy
+7,414
New +$214K ﹤0.01% 784
2020
Q4 		– Sell
-74,713
Closed -$1.88M – 1064
2020
Q3 		$1.88M Sell
74,713
-50,498
-40% -$1.32M 0.02% 439
2020
Q2 		$3.06M Buy
+125,211
New +$2.47M 0.04% 421

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Martingale Asset Management's RVNC Position: Q4 2021 in Review

Martingale Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 28,914 shares — an estimated $806K sold.

Martingale Asset Management first reported a position in RVNC in Q2 2020 and held it in 4 quarters. The position peaked at $3.06M in Q2 2020. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • Martingale Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Martingale Asset Management sold 28,914 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $806K.
  • Martingale Asset Management first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
  • Martingale Asset Management's Revance Therapeutics, Inc. position peaked at $3.06M in Q2 2020.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on Martingale Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.